Khimki

Researchers are evaluating the efficacy and safety of the drug Reamberin solution for infusion, 1.5%, for treating viral enteric infection in children aged 1 to 6 years. This study focuses on children of both sexes diagnosed with viral and other specified intestinal infections who show clinical signs of endogenous intoxication and require infusion therapy. The trial aims to understand how well Reamberin works and how safe it is when used as part of routine clinical care. Participants receive Reamberin at a daily dose of 10 mL per kg of body weight along with fluids such as normal saline, glucose solutions, or Ringer's solution. The treatment is given by infusion under the supervision of a physician. The study is observational, involving monitoring children who have been prescribed Reamberin and supportive fluids as part of their treatment. During the study, researchers assess how many children continue infusion therapy at 24 and 48 hours after starting treatment, the average duration of infusion therapy, and symptom duration related to gastrointestinal damage and intoxication. They also evaluate the severity of illness 48 hours after treatment begins and how long children stay in the hospital. Parents or legal representatives provide informed consent, and the total participation includes treatment and monitoring of outcomes in a clinical setting.